Skip to content

Cinnamon and Withania on Weight Loss

Effect on Weight Loss of an Oral Association of Cinnamon Bark (Cinnamomum Cassia) and Withania Somnifera in Adult Patients With Overweight or Obesity: a Randomized, Prospective, Placebo-controlled, Multicenter, Cross-over, Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05210218
Enrollment
40
Registered
2022-01-27
Start date
2018-01-01
Completion date
2019-06-01
Last updated
2022-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

With the prevalence of obesity soaring and the absence of an effective and safe treatment that is low-cost and always feasible, the use of food supplements has gained attention for the potential benefits in the absence of significant safety concerns. Cinnamon (CC) and Withania somnifera (WS) are plant-based supplements reported to be effective in improving metabolic health and body composition, the first mainly acting on insulin resistance and the second on energy expenditure and leptin resistance, as shown in preclinical and some clinical studies. Their association, possibly synergistic leveraging different mechanisms of action, has never been studied. This was a double-blind placebo-controlled study. Patients with overweight or obesity were prescribed a mildly hypocaloric diet with CC 300 mg plus WS 150 mg tid for 4 weeks in a cross over design and anthropometric parameters together with safety outcomes were collected.

Interventions

DIETARY_SUPPLEMENTCinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively)

The study product, in a capsule formulation, was made by the extract of Cinnamomum cassia (CC) and Withania somnifera (WS) (300 mg+150mg, respectively) (Nutrintech Ltd., London, UK)

DIETARY_SUPPLEMENTplacebo

cellulose

Sponsors

University of Roma La Sapienza
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
25 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* age range: 25-75 years * overweight or obesity (BMI range: 26-35)

Exclusion criteria

* heart failure * congenital cardiomyopathies * episodes of tachy/brady-arrythmias * acute myocardial infarction within 3 months from the enrollment * inability or unwillingness to provide informed consent * pregnancy

Design outcomes

Primary

MeasureTime frameDescription
weight changeat baseline and at every follow up visit, through study completion, an average of 10 weeksbody mass change in kg

Secondary

MeasureTime frameDescription
waist circumference changeat baseline and at every follow up visit through study completion, an average of 10 weekswaist circumference change in cm

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026